. 2022 May 3;198(6):507–526. doi: 10.1007/s00066-022-01942-1

Table 11.

Trials evaluating interferon-alpha2a as a radiosensitizer, sorted by publication year

Author	Year	Agent	Dose	n	Radiation regimen	Results
Dillman et al. [75]	1995	IFN-alpha2a	3–5 million IU sc. for 3 days/week	19 (12)	59.4 Gy in 33 fractions	Median OS: 7.4 months
Dillman et al. [77]	2001	IFN-alpha2a	3–6 million IU s.c. qid for 3 days/week	40 (36)	59.4 Gy in 33 fractions	Median OS: 9.3 months
CRA	1 mg/kg qid for 5 days/weeks

Author

Year

Agent

Dose

Radiation regimen

Results

Dillman et al. [75]

1995

IFN-alpha2a

3–5 million IU sc.

for 3 days/week

19 (12)

59.4 Gy in 33 fractions

Median OS: 7.4 months

Dillman et al. [77]

2001

IFN-alpha2a

3–6 million IU s.c. qid

for 3 days/week

40 (36)

59.4 Gy in 33 fractions

Median OS: 9.3 months

CRA

1 mg/kg qid

for 5 days/weeks

n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)